Articles Efficacy and safety of biosimilar CTP13 compared with originator infliximab in patients with active Crohn's disease an international randomised doubleblind phase 3 noninferiority study

This study showed noninferiority of CTP13 to infliximab in patients with active Crohn's disease. Biosimilar CTP13 could be a new option for the treatment of active Crohn's disease.